Patrick joined Relypsa in May 2015 as Vice President of Sales, where he assisted with the successful launch of Relypsa’s first commercial product. In April 2017 he was appointed Senior Vice President and Chief Commercial Officer of Relypsa and in 2018, he was promoted to President. He has more than 20 years of experience in the pharmaceutical industry in sales, marketing, managed markets and training and development, and over 10 years of senior leadership experience. Prior to Relypsa, Patrick served as Vice President of Sales and Managed Markets at Insulet Corporation, a medical device company. Before Insulet, he served as Vice President of U.S. Sales at AMAG Pharmaceuticals, where he assisted in the buildout of its first commercial team and successful launch of its first brand. Earlier in his career, Patrick held positions of increasing responsibility at Johnson and Johnson, Abbott Laboratories and Oscient Pharmaceuticals including roles as District Sales Manager, Brand Manager, Director of Sales Training and National Sales Director. Patrick earned a B.S. in management from Bryant University and an M.B.A. from Rensselaer Polytechnic Institute.
Senior Vice President, General Counsel and Head of U.S. Site Operations
Deborah joined Relypsa in September 2014 and now serves as Senior Vice President, General Counsel and Head of U.S. Site Operations. Prior to Relypsa, Deborah was Vice President of Legal Services at Exelixis, where she helped the company prepare for the U.S approval and commercial launch of Cometriq® for the treatment of progressive, metastatic medullary thyroid cancer. During her 10 years at Exelixis, she built the company’s legal transactions team and worked on a variety of transactions to support the research, development, partnering and commercialization of drug products. She also initiated the company’s healthcare compliance program. Before Exelixis, Deborah served as in-house counsel at Peninsula Pharmaceuticals. Earlier in her career, she was an Associate in the Life Sciences Transactions Practice Group at Cooley LLP. Deborah received a B.S. in biological sciences from the University of California, Davis, and a J.D. from Santa Clara University Law School.
Vice President of Human Resources
Laurie joined Relypsa in 2016 with more than 25 years of experience in human resources, talent development, facilitation/coaching and improving organizational effectiveness. Prior to Relypsa, she was responsible for the evolution and development of change leadership practices, standards, tools and guidelines as a senior manager in talent development at Intuit, Inc. She partnered with executives across the legal, corporate affairs, big data engineering and analytics and information security organizations to drive key strategic outcomes and decisions on talent, organizational effectiveness, strategic capability and leadership. Prior to Intuit she served as Director, HR Business Partner for Altera Corporation. While there, she also served as the Director of Learning and Organizational Effectiveness and established a leadership framework and development program. Earlier in her career, Laurie was a senior training consultant providing instructional design, leadership development training and worldwide sales training to Cisco Systems. She was also a technical trainer for Quantum Corporation and Unisys Corporation. Laurie received a B.A. in organizational communication with a concentration in marketing from Arizona State University.
Vice President of Medical and Scientific Affairs
Alain joined Relypsa in August 2015 with 25 years of experience in clinical research and development, medical affairs and business development. He has led clinical programs across a wide range of therapeutic areas, including drug delivery, anti-infectives, neuroscience, cardiovascular and respiratory medicine, resulting in the successful filing and launch of several new pharmacological treatments. Before joining Relypsa, Alain was Vice President of Medical Affairs at Actelion, where he launched Opsumit® for pulmonary arterial hypertension. Previously, Alain spent 18 years at Pfizer, where he worked in early clinical research on licensing assets to late-stage development, domestically and internationally, before becoming responsible for Medical Affairs. Prior to joining the biotechnology/pharma industry, Alain practiced at the Rennes University Hospital, was a Research Fellow at Ciba-Geigy, and served as a consultant for several companies and on FDA-mandated audits. He was an Adjunct Professor of Medicine at the University of Rennes and the Miller Medical School in Miami. Alain has a Pharm.D. from the University of Rennes School of Medicine and Pharmacy and a Ph.D. in biomedical and pharmaceutical sciences from the University of Rhode Island.
Vice President of Finance
James joined Relypsa in March 2014 and has had increasing responsibility during his tenure with the Company. He has more than 15 years of experience in the biotechnology/pharmaceutical industry in the areas of corporate finance, financial planning and analysis, accounting operations and collaborations. Prior to joining Relypsa, James served as Director, Financial Planning and Analysis, at Exelixis. Before that, he held management roles at Titan Pharmaceuticals and Affymax. He received a B.S. in business administration from the University of San Francisco and an M.B.A. with a concentration in finance from Golden Gate University.
Vice President and Chief Commercial Officer
Todd joined Relypsa in 2014 and has over 25 years of pharmaceutical and biotechnology experience launching products in a variety of therapeutic areas and building high performing Commercial teams. Since joining Relypsa, Todd has played a pivotal role in the launch and subsequent commercialization of Veltassa (patiromer) in the United States. In his current role, he is responsible for driving strategy and revenue generation for Relypsa’s product portfolio, including a recent commercial partnership with Janssen Pharmaceuticals to launch the new renal indication for Invokana (canagliflozin). Todd is a passionate leader in driving our patient centric approach. Outside of leading our Commercial organization, Todd has a personal commitment to fighting kidney disease and serves on the NKF Board of Directors, is the chair of the Bay Area Kidney Walk Executive Leadership Committee, and has been a top national fundraiser for the National Kidney Foundation (NKF) for several years. Todd began his career at Pfizer serving in various roles of increasing responsibility, starting out in Sales and moving into roles in Sales Leadership and Marketing. At Pfizer, Todd was part of the Lipitor marketing team and led Marketing for Latin America where he oversaw the launch of Eliquis (apixaban) across the region. Todd also worked at Vertex Pharmaceuticals where he supported the launch of a new therapeutic class to eradicate the Hepatitis C virus (telaprevir). Todd received a B.S. in Microbiology & Immunology from the University of Arizona with a minor in Chemistry.